Benazepril at incremental doses in essential hypertension

R. Fogari, F. Tettamanti, L. Poletti, G. Malamani, M. Sardina, S. Savonitto

Research output: Contribution to journalArticlepeer-review


The antihypertensive effect of the new non-sulphydryl ACE-inhibitor benazepril was studied in 30 patients (16 men, 14 women; mean age 50 ± 7 years) with essential hypertension at WHO stage I or II. After a 2-week placebo treatment, patients with lying diastolic blood pressure (DBP) ≥95 mmHg were given benazepril 10 mg once daily for 2 weeks. At the end of this period, patients with lying DBP

Original languageEnglish
Pages (from-to)63-66
Number of pages4
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Issue number2
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology


Dive into the research topics of 'Benazepril at incremental doses in essential hypertension'. Together they form a unique fingerprint.

Cite this